GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
September 26, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against...
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
February 08, 2023 09:00 ET
|
GeoVax, Inc.
Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Announces Issuance of Hepatitis B Vaccine Patent
July 07, 2021 09:00 ET
|
GeoVax, Inc.
Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide ATLANTA, GA, July 07, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the...